Yükleniyor... / Loading...
Eltrombopag for Treatment of Fanconi Anemia
Bu çalışma, Fanconi anemisi (Fanconi anemia) olan çocuklarda Eltrombopag adlı ilacın etkisini incelemektedir. Çalışmaya, tanısı doğrulanmış, klinik olarak anlamlı kan hücresi düşüklüğü (sitopeni) bulunan 4-17 yaş arası hastalar alınmıştır. Çalışma Faz 2 aşamasında yürütülmüş ve tamamlanmıştır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: * Patients with a diagnosis of Fanconi anemia. Diagnosis will be defined by the presence of biallelic mutations in genes known to cause the disease and/or by positive chromosome breakage analysis of lymphocytes and/or skin fibroblasts (for cases of mosaicism). * Age from 4 to ≤ 17 years. * Lansky index \> 80%. * Informed consent provided in accordance with current legislation. * Presenting with one or more of one of the following clinically significant cytopenias: platelet count ≤ 50x109/L or transfusion dependence, having required at least 2 transfusions in the 8 weeks prior to inclusion in the study; granulocyte count \< 0.75x109/L; hemoglobin \< 9 gr/dL or transfusion-dependent anemia having received 2 transfusions in the 8 weeks prior to inclusion in the study. Exclusion Criteria: * Patients with HLA-matched related donor or unrelated donor with a 12/12 match who is immediately available. * Evidence of myelodysplastic syndrome or leukemia or cytogenetic abnormalities predictive of these disorders in bone marrow aspirates. In the event, the evaluations performed two months before patient inclusion in the clinical study will be considered valid. * Baseline creatinine greater than 2.5 times the upper limit of normality. * GOT/AST or GPT/ALT more than three times the upper limit of normality. Direct bilirubin greater than 1.5 times the upper limit of normality. * Patients who are already receiving treatment with some drug for bone marrow failure may be included as long as the dose administered remains stable for at least two months. In the event that such treatment requires an increase in dose during the study, the patient must withdraw from the trial. Patients who have already started Revolade® treatment in the previous two months may also be included, and the blood counts and baseline bone marrow studies performed at the start of treatment will be used. * Women of postpubertal age and therefore at risk of pregnancy should have a negative serum or urine pregnancy test at the screening visit and agree to use a contraceptive method throughout the treatment period and for at least one month after.